A non-opioid pathway for dynorphin-caused spinal cord injury in rats

Yu Chen, Liangbi Xiang, Jun Liu, Dapeng Zhou, Hailong Yu, Qi Wang, Wenfeng Han, Mingming Guo

Department of Orthopedics, General Hospital of Shenyang Military Area Command of Chinese PLA, Shenyang 110016, Liaoning Province, China

Abstract
Intrathecal injection of dynorphin into rats via subarachnoid catheter induces damage to spinal cord tissue and motor function. Injection of the kappa opioid receptor antagonist nor-binaltorphine, or the excitatory amino acid N-methyl-D-aspartate receptor antagonist MK-801 into rats alleviated the pathological changes of dynorphin-caused spinal cord tissue injury and reduced the acid phosphatase activity in the spinal cord. The experimental findings indicate that there are opioid and non-opioid pathways for dynorphin-induced spinal cord injury, and that the non-opioid receptor pathway may be mediated by the excitatory amino acid N-methyl-D-aspartate receptor.

Key Words: spinal cord injury; dynorphin; kappa opioid receptor antagonist; N-methyl-D-aspartate receptor antagonist; motor function; acid phosphatase

INTRODUCTION
Endogenous opioid peptide is a leading factor of secondary pathological damage following traumatic and irreversible spinal cord injury[^1]. However, whether this injury has an underlying mechanism involving an opioid or non-opioid pathway remains unclear[^1-6]. Faden[^6] reported that an endogenous opioid peptide, dynorphin, works mainly depending on its specific receptor, the kappa receptor, and thus this receptor may need to be targeted for treatment of spinal cord injury. Indeed, kappa receptor antagonists can significantly alleviate the degree of spinal cord injury. The non-specific opioid receptor antagonist, naloxone, has been shown to antagonize dynorphin-caused spinal cord injury, although the effect is not significant, indicating that dynorphin-induced spinal cord injury may be achieved via opioid-like and non-opioid-like receptor mechanisms[^7-9]. Isaac et al[^9] have demonstrated that competitive excitatory amino acid N-methyl-D-aspartate (NMDA) receptor antagonists can block dynorphin-induced loss of tail-flick reflex in the rat. Previous studies performed by our research group have demonstrated that pre-intrathecal injection of excitatory amino acid NMDA receptor antagonist MK-801 could significantly reduce the dynorphin-caused impairment on neurological function and histopathology in rats. Furthermore, this reduction occurred in a dose-dependent fashion[^10]. This study therefore aimed to verify whether a non-opioid pathway of dynorphin-induced spinal cord injury may be mediated via the NMDA receptor.

RESULTS
Quantitative analysis of experimental animals
A total of 81 Sprague-Dawley rats were included in this study, after 11 rats were excluded due to damage in spinal subarachnoid catheterization, the remaining 70 rats were randomly divided into four groups: control group (n = 16; intrathecal injection of saline); dynorphin group (n = 18; intrathecal injection of saline + dynorphin A (1-13)); dynorphin + nor-binaltorphine (nor-BNI) group (n = 18; intrathecal injection of nor-BNI + dynorphin A (1-13)); and dynorphin + MK-801 group (n = 18; intrathecal injection of MK-801 + dynorphin A (1-13)). At 3 and 14 days after injection, eight animals from the control group and nine animals from the other three groups were collected and observed. Overall, 70 Sprague-Dawley rats were involved in the result analysis.

Effect of kappa opioid receptor antagonist nor-BNI and NMDA receptor antagonist MK-801 on motor functions with dynorphin-induced spinal cord injury
The critical angle of Rivlin’s oblique plate in the dynorphin group was significantly
increased compared with the control group at 3 days post-injection \((P < 0.05)\). This critical angle slightly recovered at 14 days, but was still larger than the other three groups \((P < 0.05)\). The altered value of critical angle in Rivlin's oblique plate test was significantly reduced in the dynorphin + nor-BNI group and the dynorphin + MK-801 group compared with the dynorphin group at 14 days post-injection \((P < 0.05); \text{Table 1}\).

### Table 1 Comparison of motor function [critical angle of Rivlin's oblique plate (*)] in rats

| Group                        | Time after injection (day) |
|------------------------------|----------------------------|
| Control                      | 3.91±2.56                  |
| Dynorphin                    | 32.26±12.60*               |
| Dynorphin + nor-binaltorphine| 33.49±2.17*               |
| Dynorphin + MK-801           | 32.57±5.79*               |

| Group                        | Time after injection (day) |
|------------------------------|----------------------------|
| Control                      | 7.65±6.40                  |
| Dynorphin                    | 20.17±7.60*               |
| Dynorphin + nor-binaltorphine| 6.38±0.75*               |
| Dynorphin + MK-801           | 5.05±2.70*               |

Eight rats were used in the control group and nine rats in the other three groups at each time point. Data were expressed as mean ± SD and difference between groups was compared with one-way analysis of variance and Student-Newman-Keuls test. *\(P < 0.05\), vs. control group; *\(P < 0.05\), vs. dynorphin group.

### Effect of nor-BNI and MK-801 on spinal cord morphology in rats with dynorphin-induced spinal cord injury

Hematoxylin-eosin staining showed that edema was visible in the injected spinal cord in the dynorphin group at 3 days after intrathecal injection. Massive hemorrhage and necrotic tissue were observed in gray matter and white matter. The structure of the central canal was damaged, and neuronal vacuoli were degenerated. Furthermore, some nuclei were concentrated, dissolved, small and triangular in shape. Inflammatory leukocytes infiltrated the white matter, where nerve fibers were disrupted and demyelinated. The distribution of the white matter appeared disordered and the amount was significantly reduced. Spinal cord edema was also apparent in the dynorphin + nor-BNI group and the dynorphin + MK-801 group. The central gray matter developed spotty bleeding, which was more apparent in the dynorphin + MK-801 group. The central canal still appeared to bleed and was damaged, although a small amount of neuronal degeneration, pyknosis, and white matter demyelination were visible (Figure 1). At 14 days post-intrathecal injection, spinal cord edema disappeared in all groups. In the dynorphin group, a liquefactive necrotic area was wrapped with massive fibers. White matter fibers had proliferated in a disorderly manner. No inflammatory cells had infiltrated the spinal cord, but neuronal degeneration and nuclear pyknosis was still present. By contrast, in the dynorphin + nor-BNI group and the dynorphin + MK-801 group, focal necrosis and gliocytes proliferated. The majority of neurons retained their normal morphology with staining appearing normal. For example, nerve fibers in the white matter were arranged in a tight and orderly fashion. There was no significant difference between the dynorphin + nor-BNI group and the dynorphin + MK-801 group (Figure 2).

**Figure 1** Morphology of rat spinal cord tissue at 3 days after intrathecal injection of MK-801 (N-methyl-D-aspartate receptor antagonist) or nor-binaltorphine (nor-BNI, kappa opioid receptor antagonist) (hematoxylin-eosin staining).

Control group: Gray and white matter were normal (A, \(\times 40\)).

Dynorphin group: Massive gray matter necrosis and hemorrhage (B, \(\times 40\)). Severe edema of white matter and inflammatory cell infiltration (C, \(\times 40\)) were observed.

Dynorphin + nor-BNI group: White matter edema, fiber disorder and demyelination were observed (D, \(\times 40\)).

Dynorphin + MK-801 group: Gray matter necrosis, hemorrhage, and inflammatory cell infiltration (E, \(\times 20\); F, \(\times 40\)) were observed.
Effect of nor-BNI and MK-801 on acid phosphatase (ACP) expression in rats with dynorphin-induced spinal cord injury

Immunohistochemical detection analysis showed that ACP activity in spinal cord anterior horn cells was normal in control rats at 3 days post-injection. Enzyme reaction particles were small, yellow, and uniformly distributed in the cytoplasm. The nuclei and nucleoli were clearly visible. In the dynorphin group, ACP activity in the spinal cord anterior horn cells was significantly enhanced and the number of reaction particles was increased ($P < 0.05$). Particles were thick and brownish and the nuclei were covered with dense enzyme reaction particles. ACP activity was slightly increased in the dynorphin + nor-BNI and dynorphin + MK-801 groups. Enzyme reaction particles were tiny, but the number of particles was higher in these groups than in the control group and lower than the dynorphin group ($P < 0.05$). There was no significant difference between the groups treated with nor-BNI and MK-801 (Table 2, Figure 3). At 14 days after injection, the ACP activity decreased in all groups. The number of enzyme reaction particles reduced and particles were evenly distributed. The ACP activity was still at high levels in some sections from the dynorphin group, but no significant difference was observed compared with other groups (Table 2, Figure 3).

Figure 2  Morphology of rat spinal cord tissue at 14 days after intrathecal injection of MK-801 (N-methyl-D-aspartate receptor antagonist) or nor-binaltorphine (nor-BNI, kappa opioid receptor antagonist) (hematoxylin-eosin staining, × 20).

(A) Gray matter was normal in the control group.
(B) In the dynorphin + nor-BNI group, white matter edema disappeared and fibers were slightly demyelinated.
(C) A small area of liquefaction necrosis was visible in the dynorphin + MK-801 group.
(D) In the dynorphin group, liquefaction necrosis was wrapped with fibers.

Figure 3  Acid phosphatase (ACP) activity in the spinal anterior horn after intrathecal injection of MK-801 (N-methyl-D-aspartate receptor antagonist) or nor-binaltorphine (nor-BNI, kappa opioid receptor antagonist) (histochemical staining, × 40).

At 3 days after intrathecal injection, ACP reaction particles were light yellow and evenly distributed in the control group. In the dynorphin + nor-BNI group, ACP reaction particles were brownish yellow and cellular morphology was normal. Similar observations were seen in the dynorphin + MK-801 group. ACP reaction particles were brownish black and thick, with an irregular cell morphology being seen in the dynorphin group.

At 14 days after intrathecal injection, ACP reaction particles were uniformly distributed and stained as light yellow in the control group. In the dynorphin + nor-BNI group, ACP reaction particles at 14 days after intrathecal injection were stained lighter than at 3 days, showing a light yellow color. The ACP reaction particles at 14 days after intrathecal injection in the dynorphin + MK-801 group were stained lighter than at 3 days. ACP reaction particles at 14 days after intrathecal injection were stained brown yellow in the dynorphin group, which was lighter than at 3 days, and cellular morphology was normal.
ACP is a lysosomal marker and can be released when cells are injured. Enhanced activity of ACP reflects the increased number and active function of lysosomes. The increased release of lysosomal enzymes leads to cell damage and even death. In this study, ACP activity was reduced or returned to normal after treatment with the NMDA receptor antagonist, MK 801, and the kappa receptor antagonist, nor-BNI. In addition, the impairment of motor function and spinal cord tissue was also reduced or returned to normal after treatment with MK-801 and NMDA receptors to do so, indicating that the kappa receptor antagonist and NMDA receptor can alleviate dynorphin-induced spinal cord injury. This is consistent with previous findings. Nor-BNI and MK-801 can be used to treat injury, but they respectively depend on blocking kappa and NMDA receptors to do so, indicating that the effects of dynorphin are interrelated with kappa and NMDA receptors. This is possibly why nor-BNI and MK-801 cannot completely block the pathological effects of dynorphin. The underlying mechanism could be as follows: (1) subarachnoid space injection of Dynorphin results in decreased local spinal cord blood flow, causing ischemia. The secretion of excitatory amino acids, such as glutamate and aspartic acid, increases after spinal cord ischemia, thus causing over-excitation of the NMDA receptor. This excitation in turn causes massive Ca\(^{2+}\) entry into postsynaptic neurons and induces membrane depolarization. The free fatty acid content in neurons is then increased, ultimately leading to neuronal damage. (2) Dynorphin is dependent on a presynaptic mechanism that increases excitatory amino acid concentrations or enhances excitatory amino acid activity, rather than directly causing spinal cord ischemia. (3) Dynorphin can directly act on certain sites of the NMDA receptor and trigger NMDA receptor depolarization.

In conclusion, this study suggested that there are two pathological mechanisms underlying the action of dynorphin, an opioid and a non-opioid pathway. The potential receptor involved in the non-opioid pathway is the NMDA receptor. Further studies are required to conclusively determine the exact role of NMDA receptors in non-opioid mechanisms underlying the action of dynorphin. The interaction between this non-opioid pathway and the opioid pathway also needs further elucidation. Additionally, studies regarding whether dynorphin enhances NMDA receptor activity through excitatory amino acid modulation or directly through the NMDA receptor, are also required.

**MATERIALS AND METHODS**

**Design**
A randomized controlled animal study.

**Time and setting**
Experiments were performed in the Animal Center of the Second Military Medical University of Chinese PLA, China.

**Materials**
A total of 81 healthy, male Sprague-Dawley rats, aged 2 months, weighing 300–350 g, of clean grade, were provided by the Animal Center of the Second Military Medical University of Chinese PLA, China (license No. SCXK (Hu) 2002-0006). All rats were housed under natural light/dark cycle, allowing free access to food and water. All experimental disposal of animals was in accordance with the *Guidance Suggestions for the Care and Use of Laboratory Animals*, issued by the Ministry of Science and Technology of China.

**Methods**

**Subarachnoid cannulation**
Subarachnoid cannulation was performed using the modified Lopachin method. In brief, when clear cerebrospinal fluid outflow was visible, a PE-10 polyethylene tube filled with 7 μL normal saline was inserted into the subarachnoid space (7.0 cm) until it reached the level of T10-T11. Soft tissue was sutured together, layer by layer, and the polyethylene tube was fixed in the soft tissue around the wound. Rats recovered for 3 days, and were allowed free movement.

**Drug injection**
Control group: Rats were intrathecally injected with 10 μL saline. Dynorphin group: Rats were intrathecally injected with saline + 30 nM dynorphin A (1–13) (Sigma, St. Louis, MO, USA). Dynorphin + nor-BNI group: Rats were intrathecally injected with 100 nM nor-BNI (Sigma) + 30 nM dynorphin A (1–13). Dynorphin + MK-801 group: Rats were intrathecally injected with 100 nM MK-801 (Sigma) + 30 nM dynorphin A (1–13). All injected drugs were prepared with saline into 10 μL solution prior to use, dynorphin A (1–13) was given at 15 minutes after intrathecal injection of nor-BNI or MK-801. All drugs were mixed with saline immediately before injection.

**Table 2** Comparison of acid phosphatase activity in spinal anterior horn lateral neurons of rats

| Group                  | Mean gray value (%) | Equivalent circular diameter of positive particles (nm) |
|------------------------|---------------------|--------------------------------------------------------|
|                        | 3 days  | 14 days  | 3 days  | 14 days  |
| Control                | 36.8±1.2| 37.6±1.2| 20.3±5.1| 20.5±5.7|
| Dynorphin              | 48.3±1.4a | 43.8±1.6| 36.0±5.0a | 28.1±5.3|
| Dynorphin + nor-BNI    | 40.2±1.8ab | 37.4±1.6| 28.6±5.1ab | 24.8±6.1|
| Dynorphin + MK-801    | 41.0±1.5ab | 38.9±1.5| 30.2±5.6ab | 25.1±6.0|

Lower mean gray value indicates a lower acid phosphatase activity. Eight rats were used in the control group and nine rats were used in the other three groups at each time point.

Data were expressed as mean ± SD and difference between groups was compared with one-way analysis of variance and Student-Newman-Keuls test. *P < 0.05, vs. control group; **P < 0.05, vs. dynorphin group.
injected within 2 minutes.

**Assessment of motor function in rats by Rivlin’s oblique plate test**

We used a Rivlin oblique plate \([28]\). This plate was a wooden half-arc structure, 40 cm wide and 50 cm long. Angles were marked on both sides, and the moveable plate was designed with an adjustable angle of 0°–90°. The plate surface was covered with a rubber pad, 40 cm long and 30 cm wide. This pad was attached with several parallel shallow grooves, at a depth of 0.3 cm and at 1.6 cm intervals (supplementary Figure 1 online). At 3 and 14 days after injection, rat motor function was investigated using a modified Rivlin method \([28]\). The rat head faced forward, the body’s longitudinal axis was perpendicular to the oblique plate longitudinal axis. The angle between the plate and the horizontal plane was then gradually increased, until the rats could maintain just 5 seconds in a constant position, deemed the critical angle. The critical angle was recorded and the change in angle before and after injection was calculated. The gripping ability of the rat limb determines the angle, thus reflecting spinal cord nerve function in rats. Each rat was measured three times and the mean value was calculated.

**Morphology of spinal cord T10-12 segments**

After the oblique plate test was completed, rats were killed under deep anesthesia via intraperitoneal injection of 70 mg/kg phenobarbital sodium. T10-12 segments of spinal cord were fixed, paraffin-embedded and cut into consecutive slices at 10 µm thickness. Three serial slices were randomly selected from each tissue for hematoxylin-eosin staining and observation under a light microscope (Olympus, Tokyo, Japan).

**Histochemical staining of ACP**

T10-12 segments of the rat spinal cord were cut into consecutive frozen slices (20 µm), and three consecutive slices were randomly selected from each tissue for ACP histochemical staining. In brief, frozen slices were dried, incubated with culture medium at 37°C for 3 hours, and rinsed with double distilled water. Slices were then incubated with 2% acetic acid for 1 minute and rinsed again with double distilled water, whereupon they were incubated with 1% ammonium sulfide for 1 minute and repeatedly rinsed with tap water. After rinsing, slices were incubated with 2% methyl green counter-stain (for nuclei) for several minutes and then dried and dehydrated with 96% and 100% ethanol, respectively. Following this, slices were fixed using xylene transparency and gum cementing. The mean gray and equivalent circle diameter of ACP positive particles in spinal cord anterior horn neurons were automatically acquired using a modified Rivlin method \([28]\). The mean gray and equivalent circle diameter of ACP positive particles in spinal cord anterior horn neurons were automatically acquired using a modified Rivlin method \([28]\). The mean gray and equivalent circle diameter of ACP positive particles in spinal cord anterior horn neurons were automatically acquired using a modified Rivlin method \([28]\). The mean gray and equivalent circle diameter of ACP positive particles in spinal cord anterior horn neurons were automatically acquired using a modified Rivlin method \([28]\).

**Statistical analysis**

Data are expressed as mean ± SD and differences between groups were compared with one-way analysis of variance and Student-Newman-Keuls test.

**Funding**: This study was supported by the Science and Key Technology Research and Development Program of Liaoning Province, No. 2011225021, 2011225041.

**Author contributions**: All authors were responsible for study design, implementation and assessment.

**Conflicts of interest**: None declared.

**Ethical approval**: The experiments were approved by Animal Ethics Committee at the Second Military Medical University of Chinese PLA in China.

**Supplementary information**: Supplementary data associated with this article can be found, in the online version, by visiting www.nrnonline.org, and entering Vol. 7, No. 11, 2012 item after selecting the “NRR Current Issue” button on the page.

**REFERENCES**

[1] Li M, Ye XJ, Fu XH, et al. Effect of dynorphin and excitatory amino acid on spinal cord injury in rats. Shiyong Guke Zazhi. 1999;5(3):145-148.

[2] Zhang L, Peoples RW, Oz M, et al. Potentiation of NMDA receptor-mediated responses by dynorphin at low extracellular glycine concentrations. J Neurophysiol. 1997;78(2):582-590.

[3] McIntosh TK, Fernyak S, Yamakami I, et al. Central and systemic kappa-opioid agonists exacerbate neurobehavioral response to brain injury in rats. Am J Physiol. 1994;267(3 Pt 2):R665-672.

[4] Laughlin TM, Vanderah TW, Lashbrook J, et al. Spinally administered dynorphin A produces long-lasting alldynia: involvement of NMDA but not opioid receptors. Pain. 1997;72(1-2):253-260.

[5] Isaac L, Van Zandt O’Malle T, Ristic H, et al. MK-801 blocks dynorphin A (1-13)-induced loss of the tail-flick reflex in the rat. Brain Res. 1990;531(1-2):83-87.

[6] Faden AI. Experimental neurobiology of central nervous system trauma. Crit Rev Neurobiol. 1993;7(3-4):175-186.

[7] Tang Q, Gandhoke R, Burritt A, et al. High-affinity interaction of (des-Tyrosyl)dynorphin A(2-17) with NMDA receptors. J Pharmocol Exp Ther. 1999;291(2):760-765.

[8] Chen Y, Li M, Hou TS, et al. Study of the receptor mechanism of dynorphin-induced loss of spinal reflex. Zhonghua Shiyan Waeke Zazhi. 2001;18(4):357-358.

[9] Bian D, Ossipov MH, Ibrahim M, et al. Loss of antiallodynic and antiinflammatory properties of dynorphin-induced loss of spinal reflex. Zhonghua Shiyan Waeke Zazhi. 2001;18(4):357-358.

[10] Chen Y, Zu QM, Yan WJ, et al. Effects and receptor mechanism of dynorphin-induced loss of spinal reflex. Zhonghua Shiyan Waeke Zazhi. 2001;18(4):357-358.

[11] Shi X, Zhang L, Tong Y, et al. A model of spinal cord injury in rats: restoration by MK-801 or dynorphin antisera. Brain Res. 1999;831(1-2):55-63.

[12] Li M, Chen Y, Hou TS, et al. Research on mechanism of non-opioid receptor in dynorphin-induced spinal cord injury. Di’er Junyi Daxue Xuebao. 2001;22(10):924-927.

[13] Sowa NA, Stree SE, Vinho P, et al. Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2010;30(31):10282-10293.

[14] Yang Y, Bai X, Dong H, et al. Intracerebroventricular injection of human prostatic acid phosphatase has potent neuroprotective effects against transient focal cerebral ischemia in rats. Neurosci Lett. 2011;504(3):321-324.

[15] Chen Y, Zu QM, Yan WJ, et al. Effects and receptor mechanism of dynorphin-induced changes of behavior and spinal cord histology of rat. Jizhu Waike Zazhi. 2006;4(1):29-32.

[16] Campillo A, Cabañero D, Romero A, et al. Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice. Eur J Pharmacol. 2011;657(1-3):89-96.

[17] Kelamangalath L, Dravid SM, George J, et al. k-Opioid receptor inhibition of calcium oscillations in spinal cord neurons. Mol Pharmacol. 2011;79(8):1061-1071.
[16] Okada-Ogawa A, Kurose M, Meng ID. Attenuation of cannabinoid-induced inhibition of medullary dorsal horn neurons by a kappa-opioid receptor antagonist. Brain Res. 2010;1359:81-89.

[17] Lawson KP, Nag S, Thompson AD, et al. Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia. Pain. 2010;151(3):806-815.

[18] Theisen MM, Ploner F, Van Aken HK, et al. Pretreatment time with norbinaltorphimine. Anesth Analg. 2010;110(4):1243-1244.

[19] Schepers RJ, Mahoney JL, Gehrke BJ, et al. Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation. Pain. 2008;138(2):423-439.

[20] Liu CH, Cherng CH, Lin SL, et al. N-methyl-D-aspartate receptor antagonist MK-801 suppresses glial pro-inflammatory cytokine expression in morphine-tolerant rats. Pharmacol Biochem Behav. 2011;99(3):371-380.

[21] Esposito E, Paterniti I, Mazzon E, et al. MK801 attenuates secondary injury in a mouse experimental compression model of spinal cord trauma. BMC Neurosci. 2011;12:31.

[22] Hu WH, Zhang CH, Yang HF, et al. Mechanism of the dynorphin-induced dualistic effect on free intracellular Ca\(^{2+}\) concentration in cultured rat spinal neurons. Eur J Pharmacol. 1998;342(2-3):325-332.

[23] Koetzner L, Hua XY, Lai J, et al. Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and -2. J Neurosci. 2004;24(6):1451-1458.

[24] Woods A, Zangen A. A direct chemical interaction between dynorphin and excitatory amino acids. Neurochem Res. 2001;26(4):395-400.

[25] The ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.

[26] LoPachin RM, Rudy TA, Yaksh TL. An improved method for chronic catheterization of the rat spinal subarachnoid space. Physiol Behav. 1981;27(3):559-561.

[27] Chen Y, Li M, Yang X, et al. Effects and receptor mechanism of dynorphin-induced injury of spinal cord. Shanghai Yixue. 2005;28(11):949-951.

[28] Rivlin AS, Tator CH. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg. 1977;47(4):577-581.

[29] Silverman JD, Kruger L. Acid phosphatase as a selective marker for a class of small sensory ganglion cells in several mammals: spinal cord distribution, histochemical properties, and relation to fluoride-resistant acid phosphatase (FRAP) of rodents. Somatosens Res. 1988;5(3):219-246.

(Edited by Jia DL, Yu QJ/Yang Y/Song LP)